Private EquityScreenerRefer

MARKET INSIGHTS

  • EventsNEWPrivate market milestones
  • NewsPrecize daily pulse
  • BlogsIn-depth articles and opinions

GUIDES

Explore Now
  • Unlisted SharesStep-by-step · KYC
  • BuyingStep-by-step · KYC
  • SellingExit in 24 - 48 hours
  • Pre-IPOReturns · risks · case studies
  • Tax GuideBudget 2026 changes
  1. Home
  2. Unlisted share news
  3. Ranjan Pai’s MEMG and 360 One get CCI nod to invest in API Holdings

Ranjan Pai’s MEMG and 360 One get CCI nod to invest in API Holdings

26 Mar 2024

Add as preferred source
Key Takeaways

  • Strategic Partnership:

    • Partnership with MEMG and 360 One signals strategic alignment, laying the foundation for sustained growth and market consolidation.

  • Long-term Optimism:

    • Even though PharmEasy faces some immediate difficulties, improvements in its operations give hope that it will be successful and become a dominant player in the market over the long term.

  • Strategic Partnership:

    • Partnership with MEMG and 360 One signals strategic alignment, laying the foundation for sustained growth and market consolidation.

  • Long-term Optimism:

    • Even though PharmEasy faces some immediate difficulties, improvements in its operations give hope that it will be successful and become a dominant player in the market over the long term.

pharmeasy unlisted shares

API Holdings (Pharmeasy)

-8.09%

Expert Analysis

API Holdings Ltd. Secures Strategic Investments Amidst PharmEasy's Challenges.

Expert Analysis:

  • Strategic CCI Approval: API Holdings Ltd. secures CCI approval for CCPS B subscription by MEMG and 360 One, reinforcing strategic investment direction.

  • Significant Financial Commitment: Undisclosed investment sizes, with MEMG's speculated Rs 1,000 crore investment for an 18% stake, indicate substantial financial commitment.

  • Synergistic Leadership Collaboration: Ranjan Pai's board presence underscores synergistic leadership collaboration, aligning strategic interests for API Holdings Ltd.

  • Short-term Hurdles: PharmEasy seeks Rs 3,500 crore to repay Goldman Sachs debt. Defaulted terms led to 50% valuation drop by Janus Henderson. Neuberger Berman slashed its valuation by 21.4% to $4.4 billion from a peak of $5.6 billion.

  • Improved Fiscal Performance: PharmEasy's revenue rose by 16% to Rs 6,644 crore in FY23. Cost-cutting measures reduced losses by 16% to Rs 2,289 crore by March 2023, per TheKredible.

Publisher:Entrackr